2021
COVID‐19 outcomes in patients with autoimmune blistering disease
Hwang E, Tomayko M. COVID‐19 outcomes in patients with autoimmune blistering disease. British Journal Of Dermatology 2021, 185: 1048-1050. PMID: 34107059, PMCID: PMC8239772, DOI: 10.1111/bjd.20571.Peer-Reviewed Original Research30 Rituximab
Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.ChaptersMucous membrane pemphigoidEpidermolysis bullosa acquisitaMechanism of actionCutaneous lupusHost diseaseBullous pemphigoidPemphigus vulgarisPemphigus foliaceusRituximabB cellsUS FoodDrug AdministrationDermatologic usesMonoclonal antibodiesPemphigoidTreatmentCD20AcquisitaLupusFoliaceusGraftDiseaseAdministrationAntibodiesPharmacology
2019
A Niche for Plasma Cells: The Skin
Karaaslan S, Tomayko MM. A Niche for Plasma Cells: The Skin. Journal Of Investigative Dermatology 2019, 139: 2411-2414. PMID: 31753124, DOI: 10.1016/j.jid.2019.06.133.Peer-Reviewed Original Research